Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation

摘要

High-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT) in combination with novel agents was recently reported to lead to longer overall survival (OS) of patients with multiple myeloma (MM), resulting in a 10-year OS of almost 50% in young patients (Kumar et al, 2008; Barlogie et al, 2010). Lenalidomide maintenance treatment contributed greatly to these improvements, as shown in three recent randomized clinical trials (Attal et al, 2010; McCarthy et al, 2010; Palumbo et al, 2010). However, the Intergroupe Francophone du Myelome trial, IFM 99-02, was closed in January 2011 because significantly more secondary primary malignancies (SPM) were observed in patients who had received lenalidomide as maintenance treatment compared to patients in the placebo arm.